RecruitingNCT07508319
Role of the Immune System in Preventing Laryngeal Cancer
Laryngeal Dysplasia and Progression to Carcinoma: Investigating Genetic and Immune Alterations Predictive of Malignant Transformation
Sponsor
European Institute of Oncology
Enrollment
3 participants
Start Date
Nov 19, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
Laryngeal dysplasia and progression to carcinoma: investigating genetic and immune alterations predictive of malignant transformation
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria2
- Histopathological diagnosis of laryngeal dysplasia.
- Age >18 years and informed consent.
Exclusion Criteria5
- Prior surgical, radiotherapeutic, or oncologic treatments for head and neck regions.
- Congenital or acquired immunodeficiency disorders.
- Synchronous malignancies.
- Immunosuppressive therapy.
- Age <18 years or absence of research consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07508319
Related Trials
REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors
NCT076356411 location
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
NCT076254231 location
Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery
NCT076223811 location
Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT076017371 location
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
NCT074450481 location